# PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6

**Authors:** Jianfeng Cui, Shouzhen Chen, Xiaochen Liu, Xuewen Jiang, Guangzhou Cheng, Zhifeng Liu, Hui Zhao, Yaofeng Zhu, Benkang Shi, Yongxin Zou

PMC · DOI: 10.1038/s41419-026-08498-3 · 2026-02-23

## TL;DR

PRDM1 limits bladder cancer growth and improves treatment response by reducing CDC6 levels through suppression of OTUD6A activity.

## Contribution

The study identifies a PRDM1-OTUD6A-CDC6 regulatory axis in bladder cancer, revealing a novel tumor suppressive mechanism.

## Key findings

- PRDM1 is downregulated in bladder cancer tissues and mouse models.
- PRDM1 suppresses cell proliferation and enhances chemosensitivity by inhibiting OTUD6A-mediated CDC6 deubiquitination.
- PRDM1 expression is negatively correlated with OTUD6A and CDC6 in bladder cancer tissues.

## Abstract

PR domain zinc finger protein 1 (PRDM1) functions as a critical transcriptional repressor. The role of PRDM1 in various tumors is controversial, and its specific mechanism in bladder cancer (BCa) remains unclear. In the present study, we demonstrated that PRDM1 expression is downregulated in both human BCa tissues and BBN-induced mouse models of BCa. Gain- and loss-of-function experiments revealed that PRDM1 delays cell cycle progression, suppresses BCa cell proliferation, and enhances chemosensitivity, whereas PRDM1 knockdown promotes cell proliferation and induces chemoresistance. Ovarian tumor deubiquitinase 6 A (OTUD6A) is a deubiquitinating enzyme that prevents the proteasomal degradation of CDC6. PRDM1 directly binds to the OTUD6A promoter and suppresses its transcription, thereby reducing CDC6 deubiquitination and promoting its degradation. Knockdown of CDC6 or OTUD6A abrogates the protective effects of PRDM1 both in vitro and in vivo. Consistently, PRDM1 expression is negatively correlated with CDC6 and OTUD6A expression in BCa tissues. Collectively, these findings demonstrate that PRDM1 acts as a tumor suppressor in BCa by inhibiting OTUD6A transcription and promoting CDC6 degradation. We propose a PRDM1‒OTUD6A‒CDC6 axis model, providing novel insights into PRDM1 as a potential therapeutic target in BCa.

## Linked entities

- **Genes:** PRDM1 (PR/SET domain 1) [NCBI Gene 639], OTUD6A (OTU deubiquitinase 6A) [NCBI Gene 139562], CDC6 (cell division cycle 6) [NCBI Gene 990]
- **Diseases:** bladder cancer (MONDO:0004986)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, Nucleolin (nucleolin multifunctional protein) [NCBI Gene 17975] {aka B530004O11Rik, C23, D0Nds28, D1Nds28, Ncl, Nucl}, PLK4 (polo like kinase 4) [NCBI Gene 10733] {aka MCCRP2, SAK, STK18}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, FZR1 (fizzy and cell division cycle 20 related 1) [NCBI Gene 51343] {aka CDC20C, CDH1, DEE109, FZR, FZR2, HCDH}, CEP192 (centrosomal protein 192) [NCBI Gene 55125] {aka PPP1R62}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, SASS6 (SAS-6 centriolar assembly protein) [NCBI Gene 163786] {aka MCPH14, SAS-6, SAS6}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, PRDM1 (PR/SET domain 1) [NCBI Gene 639] {aka BLIMP-1, BLIMP1, PRDI-BF1}, USP7 (ubiquitin specific peptidase 7) [NCBI Gene 7874] {aka C16DELp13.2, DEL16P13.2, HAFOUS, HAUSP, TEF1}, CDC6 (cell division cycle 6) [NCBI Gene 990] {aka CDC18L, HsCDC18, HsCDC6, MGORS5}, PCNT (pericentrin) [NCBI Gene 5116] {aka KEN, MOPD2, PCN, PCNT2, PCNTB, PCTN2}, CHEK1 (checkpoint kinase 1) [NCBI Gene 1111] {aka CHK1, OZEMA21}, Birc3 (baculoviral IAP repeat-containing 3) [NCBI Gene 11796] {aka Api1, Api2, C-IAP2, HIAP2, IAP1, IAP2}, DTL (denticleless E3 ubiquitin protein ligase adapter) [NCBI Gene 51514] {aka CDT2, DCAF2, L2DTL, RAMP}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Cdc6 (cell division cycle 6) [NCBI Gene 23834] {aka CDC18L, p62(cdc6)}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, PRMT5 (protein arginine methyltransferase 5) [NCBI Gene 10419] {aka HRMT1L5, HSL7, IBP72, JBP1, SKB1, SKB1Hs}, Ar (androgen receptor) [NCBI Gene 11835] {aka Tfm}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, Fdxr (ferredoxin reductase) [NCBI Gene 14149] {aka AR}, Crmp1 (collapsin response mediator protein 1) [NCBI Gene 12933] {aka CRMP-1, DRP-1, Dpysl1, ULIP-3, Ulip3}, Aurka (aurora kinase A) [NCBI Gene 20878] {aka AIRK1, ARK-1, Ark1, Aurora-A, Ayk1, IAK}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Topbp1 (topoisomerase (DNA) II binding protein 1) [NCBI Gene 235559] {aka 1110031N14Rik, 2810429C13Rik, D430026L04Rik, mKIAA0259}, Prdm1 (PR domain containing 1, with ZNF domain) [NCBI Gene 12142] {aka Blimp-1, Blimp1, PRDI-BF1, ZNFPR1A1, b2b1765Clo}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, Sting1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 72512] {aka 2610307O08Rik, ERIS, MPYS, Mita, STING, STING-beta}, KDM1A (lysine demethylase 1A) [NCBI Gene 23028] {aka AIMAH3, AOF2, BHC110, CPRF, KDM1, LSD1}, Otud6a (OTU domain containing 6A) [NCBI Gene 408193] {aka EG408193, Hshin6}, OTUD6A (OTU deubiquitinase 6A) [NCBI Gene 139562] {aka DUBA2, HSHIN6}, CCNF (cyclin F) [NCBI Gene 899] {aka FBX1, FBXO1, FTDALS5}, FGL1 (fibrinogen like 1) [NCBI Gene 2267] {aka HFREP1, HP-041, HPS, LFIRE-1, LFIRE1}, CBX8 (chromobox 8) [NCBI Gene 57332] {aka PC3, RC1}, CDK5RAP2 (CDK5 regulatory subunit associated protein 2) [NCBI Gene 55755] {aka C48, Cep215, MCPH3}, DNTT (DNA nucleotidylexotransferase) [NCBI Gene 1791] {aka TDT}
- **Diseases:** OTU (MESH:D010051), hypertrophic (MESH:D002312), B-cell lymphoma (MESH:D016393), breast cancer (MESH:D001943), kidney injury (MESH:D007674), lymphomas (MESH:D008223), BCa (MESH:D001749), DLBCL (MESH:D016403), hepatocellular carcinoma (MESH:D006528), NK cell neoplasms (MESH:D018307), leukemia (MESH:D007938), colon cancer (MESH:D015179), tumorigenic (MESH:D002471), deaths (MESH:D003643), metastases (MESH:D009362), subcutaneous (MESH:D013352), cytotoxicity (MESH:D064420), MIBC (MESH:D000093284), -N (MESH:C536108), Ataxia telangiectasia (MESH:D001260), colitis (MESH:D003092), bladder carcinogenesis (MESH:D063646), non- (MESH:C580335), colon tumor (MESH:D003110), hematological malignancies (MESH:D019337), fibrosis (MESH:D005355), intestinal inflammation (MESH:D007249), Tumor (MESH:D009369)
- **Chemicals:** Agarose (MESH:D012685), polybrene (MESH:D006583), VE-821 (MESH:C560580), TMA (MESH:C071868), alkali (MESH:D000468), PFA (MESH:C003043), CO2 (MESH:D002245), CQ (MESH:D002738), Formalin (MESH:D005557), DMSO (MESH:D004121), DAPI (MESH:C007293), PVDF (MESH:C024865), CHX (MESH:D003513), DAB (MESH:C000469), PBS (MESH:D007854), Tween-20 (MESH:D011136), Gemcitabine (MESH:D000093542), puromycin (MESH:D011691), hematoxylin (MESH:D006416), doxorubicin (MESH:D004317), crystal violet (MESH:D005840), Alexa Fluor  594 (-), H2O2 (MESH:D006861), PI (MESH:D011419), Cisplatin (MESH:D002945), nocodazole (MESH:D015739), Thymidine (MESH:D013936), BBN (MESH:D002085), dUTP (MESH:C027078), fluorescein (MESH:D019793), bortezomib (MESH:D000069286), MG132 (MESH:C072553), 5-FU (MESH:D005472), ethanol (MESH:D000431), 5-ethynyl-2'-deoxyuridine (MESH:C031086), SDS (MESH:D012967), methanol (MESH:D000432), paraffin (MESH:D010232), Triton X-100 (MESH:D017830), EDTA (MESH:D004492), xylene (MESH:D014992)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mycoplasma (genus) [taxon 2093], Mus musculus (house mouse, species) [taxon 10090], Lentivirus (genus) [taxon 11646]
- **Mutations:** cysteine residue was substituted with alanine, C152A
- **Cell lines:** S2D-F — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_A5UZ), T24 — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_0554), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), CCK-8 — Homo sapiens (Human), T-cell prolymphocytic leukemia, Cancer cell line (CVCL_5443), GR — Homo sapiens (Human), Pancreatic adenocarcinoma, Cancer cell line (CVCL_ZW95), UMUC3 — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_1783), 293 T — Homo sapiens (Human), Transformed cell line (CVCL_0063), BCa — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_S780)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966426/full.md

---
Source: https://tomesphere.com/paper/PMC12966426